ERADICATE Hp2 - Treating Helicobacter Pylori With RHB-105 Compared to Active Comparator (ERADICATE Hp2)
A Randomized Double Blind Active Comparator Controlled Phase III Study to Assess the Safety and Efficacy of RHB-105 in the Treatment of Confirmed Helicobacter Pylori (H. Pylori) Infection
Sponsor: RedHill Biopharma Limited
This PHASE3 trial investigates Dyspepsia and Helicobacter Pylori Infection and is currently completed. RedHill Biopharma Limited leads this study, which shows 8 recorded versions since 2017 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Apr 2020 — Jan 2021 [monthly]
Completed PHASE3
-
Apr 2019 — Apr 2020 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
▶ Show 3 earlier versions
-
Sep 2018 — Apr 2019 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
-
Jun 2018 — Sep 2018 [monthly]
Recruiting PHASE3
-
Jul 2017 — Jun 2018 [monthly]
Recruiting PHASE3
First recorded
Jun 2017
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- RedHill Biopharma Limited
For direct contact, visit the study record on ClinicalTrials.gov .